EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Biopsy-proven CKD etiology and outcomes: the Chronic Kidney Disease Japan Cohort (CKD-JAC) study

Takayuki Hamano, Takahiro Imaizumi, Takeshi Hasegawa iD, Naohiko Fujii, Hirotaka Komaba iD, Masahiko Ando, Masaomi Nangaku, Kosaku Nitta, Hideki Hirakata, Yoshitaka Isaka, Takashi Wada iD, Shoichi Maruyama und 1 weitere

Nephrology Dialysis Transplantation · 2023

DOI: 10.1093/ndt/gfac134 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, 2023. Verfasst von Takayuki Hamano und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Nagoya City University Graduate School of Medicine, Nagoya, Japan. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Glomerulonephritis, IGA, Diabetic Nephropathies, Glomerulonephritis, Membranous. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: KKC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The Kidney Disease: Improving Global Outcomes guidelines advocate the cause–glomerular filtration rate (GFR)–albuminuria (CGA) classification for predicting outcomes. However, there is a dearth of data supporting the use of the cause of chronic kidney disease. This study aimed to address how to incorporate a prior biopsy-proven diagnosis in outcome prediction.

Methods

We examined the association of biopsy-proven kidney disease diagnoses with kidney failure with replacement therapy (KFRT) and all-cause death before KFRT in patients with various biopsy-proven diagnoses (n = 778, analysis A) and patients with diabetes mellitus labeled with biopsy-proven diabetic nephropathy (DN), other biopsy-proven diseases and no biopsy (n = 1117, analysis B).

Results

In analysis A, adding biopsy-proven diagnoses to the GFR–albuminuria (GA) classification improved the prediction of 8-year incidence of KFRT and all-cause death significantly regarding integrated discrimination improvement and net reclassification index. Fine–Gray (FG) models with KFRT as a competing event showed significantly higher subdistribution hazard ratios (SHRs) for all-cause death in nephrosclerosis {4.12 [95% confidence interval (CI) 1.11–15.2)], focal segmental glomerulosclerosis [3.77 (95% CI 1.09–13.1)]} and membranous nephropathy (MN) [2.91 (95% CI 1.02–8.30)] than in immunoglobulin A nephropathy (IgAN), while the Cox model failed to show significant associations. Crescentic glomerulonephritis had the highest risk of all-cause death [SHR 5.90 (95% CI 2.05–17.0)]. MN had a significantly lower risk of KFRT than IgAN [SHR 0.45 (95% CI 0.24–0.84)]. In analysis B, other biopsy-proven diseases had a lower risk of KFRT than biopsy-proven DN in the FG model, with death as a competing event [SHR 0.62 (95% CI 0.39–0.97)].

Conclusions

The CGA classification is of greater value in predicting outcomes than the GA classification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Renal Insufficiency, ChronicGlomerulonephritis, IGADiabetic NephropathiesGlomerulonephritis, MembranousHumansJapanAlbuminuriaDisease ProgressionGlomerular Filtration Rate

Stichwörter der Autor:innen

CKDdiabetic kidney diseaseepidemiologykidney biopsyprognosis

Autor:innen und Institutionen

  • Department of Nephrology, Nagoya City University Graduate School of Medicine, Nagoya, Japan.
  • Department of Nephrology, Osaka University Graduate School of Medicine, Suita, Japan.
  • Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan.
  • Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Showa University Research Administration Center.
  • Department of Hygiene, Public Health, and Preventive Medicine, Graduate School of Medicine.

ORCID-Profile: Takeshi Hasegawa, Hirotaka Komaba, Takashi Wada, Masafumi Fukagawa

Förderung

  • KKC

Zitieren

APA

Hamano, T., Imaizumi, T., Hasegawa, T., Fujii, N., Komaba, H., Ando, M., Nangaku, M., Nitta, K., Hirakata, H., Isaka, Y., Wada, T., Maruyama, S., & Fukagawa, M. (2023). Biopsy-proven CKD etiology and outcomes: the Chronic Kidney Disease Japan Cohort (CKD-JAC) study. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfac134

Vancouver

Hamano T, Imaizumi T, Hasegawa T, Fujii N, Komaba H, Ando M, et al. Biopsy-proven CKD etiology and outcomes: the Chronic Kidney Disease Japan Cohort (CKD-JAC) study. Nephrology Dialysis Transplantation. 2023. doi:10.1093/ndt/gfac134

BibTeX
@article{Hamano2023,
  author = {Hamano, Takayuki and Imaizumi, Takahiro and Hasegawa, Takeshi and Fujii, Naohiko and Komaba, Hirotaka and Ando, Masahiko and Nangaku, Masaomi and Nitta, Kosaku and Hirakata, Hideki and Isaka, Yoshitaka and Wada, Takashi and Maruyama, Shoichi and Fukagawa, Masafumi},
  title = {Biopsy-proven CKD etiology and outcomes: the Chronic Kidney Disease Japan Cohort (CKD-JAC) study},
  journal = {Nephrology Dialysis Transplantation},
  year = {2023},
  doi = {10.1093/ndt/gfac134}
}
Kostenlos starten →